What are the possible causes and treatment options for hot flashes in men?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Hot Flashes in Men: Causes and Treatment

For men experiencing hot flashes, the most common cause is androgen deprivation therapy (ADT) for prostate cancer, and the most effective evidence-based treatments are gabapentin (safe and moderately effective) or venlafaxine (SSRI), with hormonal options reserved for specific circumstances. 1

Primary Causes

The predominant cause of hot flashes in men is androgen deprivation therapy (ADT) used in prostate cancer treatment, where men may remain on ADT for 2-3 years and experience significant vasomotor symptoms along with gynecomastia and anemia 1. Other causes include:

  • Hypogonadism from chemotherapy or radiation for other malignancies 1
  • Surgical orchiectomy or GnRH agonist/antagonist administration, which causes rapid testosterone decline 2
  • Breast cancer treatment in men (though less common) 3

Treatment Algorithm

First-Line: Nonpharmacologic Interventions

Start with lifestyle modifications and behavioral approaches, particularly for mild-to-moderate symptoms:

  • Weight loss if overweight or obese 1
  • Exercise and physical activity 1
  • Acupuncture - small studies show effectiveness in ADT patients 1
  • Cognitive behavioral therapy (CBT) - demonstrated reduced perceived burden of hot flashes in 68 ADT patients 1
  • Yoga, hypnosis, and lifestyle modifications 1

Second-Line: Nonhormonal Pharmacotherapy

When symptoms are disruptive to quality of life, use evidence-based nonhormonal medications:

Preferred Options:

  • Gabapentin: Proven safe and moderately effective in 2 RCTs of men with prostate cancer 1. This is the most robustly studied nonhormonal option for men specifically.

  • Venlafaxine (SSRI): Case reports and small pilot studies show improvement in hot flash symptoms in men on ADT 1. Start at 37.5 mg/day, can increase if needed 4

Alternative Nonhormonal Options:

  • Paroxetine: 10 mg/day initially 4
  • Clonidine: May help but side effects (dry mouth, postural hypotension, fatigue, constipation) often limit use 5, 6

Note: While these medications are not FDA-approved specifically for hot flashes in men, they have demonstrated clinical benefit 7

Third-Line: Hormonal Therapy (Context-Dependent)

Hormonal options depend critically on cancer status:

For Men NOT on ADT (Cured or Non-Prostate Cancer):

  • Testosterone replacement can be used for hypogonadism-related hot flashes in men who are cured of prostate cancer or have hypogonadism from chemotherapy/radiation for other malignancies 1

For Men ON ADT (Active Prostate Cancer Treatment):

Testosterone is absolutely contraindicated in men with advanced prostate malignancy on ADT 1, 2

Hormonal alternatives for ADT patients include:

  • Medroxyprogesterone acetate (MPA) 1
  • Estrogen or estrogen derivatives 1
  • Cyproterone acetate 1

These hormonal agents are more effective than nonhormonal options but carry side effects and potential risks 8

Fourth-Line: ADT Modification

If vasomotor symptoms remain severely disruptive despite pharmacotherapy, consider alternative ADT strategies with the treating oncologist:

  • Intermittent ADT 1
  • Antiandrogen monotherapy 1

What NOT to Use

Avoid these interventions due to lack of evidence or safety concerns:

  • Phytoestrogens, botanicals, and dietary supplements (category 2B) - very limited data on effectiveness and safety in men on ADT 1
  • Supplemental vitamin E - concerns about increased prostate cancer risk 1
  • Dong Quai, Serelys Homme, soy protein, Salvia officinalis - appear ineffective 8

Critical Pitfalls to Avoid

  1. Never prescribe testosterone to men with active prostate cancer on ADT - this is an absolute contraindication due to hormone-dependent cancer stimulation 1, 2

  2. Don't assume all hot flashes are treatment-related - exclude other causes when clinically indicated: hyperthyroidism, pheochromocytoma, carcinoid, panic disorder, diabetes 5

  3. Don't overlook the placebo effect - across blinded pharmacological trials, placebo effects range from 19-30% reduction in hot flash frequency 8

  4. Address the full symptom burden - men on ADT often have concurrent gynecomastia (treatable with prophylactic radiation, tamoxifen, or reduction mammoplasty) and sexual dysfunction that require separate management 1

  5. Monitor for serious adverse effects - men on tamoxifen have increased thrombotic events, particularly in the first 18 months 3

Evidence Quality Note

The strongest evidence comes from the NCCN 2017 Survivorship Guidelines 1, which specifically address ADT-related vasomotor symptoms in male cancer survivors. Gabapentin has the most robust RCT evidence specifically in men with prostate cancer, while venlafaxine evidence is based on smaller studies. The 2026 systematic review 8 confirms hormonal agents (cyproterone acetate, estrogen) are most effective but carry side effects, supporting the guideline recommendation to prioritize nonhormonal options first.

References

1
Guideline

survivorship, version 2.2017, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2017

3
Guideline

management of male breast cancer: asco guideline.

Journal of Clinical Oncology, 2020

5
Guideline

american association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2011

7
Guideline

american cancer society prostate cancer survivorship care guidelines.

Ca-A Cancer Journal for Clinicians, 2014

Related Questions

My 5-year-old child is giving inappropriate, unrelated answers to questions (e.g., "why are you digging your bat?" or "I like your dress"). What evaluations and interventions are recommended?
What history elements and examinations should be obtained when evaluating a new 62‑year‑old patient?
In a 19-year-old African American woman who does not smoke, weighs 206 lb, has no known drug allergies, and currently uses condoms, what contraceptive options are appropriate to initiate?
What is the appropriate conservative management for a 48‑year‑old patient with upper and mid‑thoracic back pain that does not limit range of motion but causes discomfort during work?
In a 78-year-old woman who is startled by moderately intense sounds, what is the appropriate evaluation and management?
What laboratory workup is indicated for a patient with suspected diabetic ketoacidosis?
Is Enhertu (fam‑trastuzumab deruxtecan‑nxki; generic: trastuzumab deruxtecan) nephrotoxic?
If a patient undergoes a gadolinium‑based contrast MRI one day before receiving Enhertu (trastuzumab deruxtecan), does the contrast affect the safety or dosing of Enhertu?
Is it appropriate to co‑prescribe benzodiazepines with stimulant medications such as methylphenidate or amphetamine‑based ADHD drugs?
What is the appropriate evaluation and management for a patient who developed new vocalizations at sleep onset after a recent heavy cough?
Is coronary artery disease the same as pulmonary embolism?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.